Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOSTER
2024-513248-27-00Phase 3Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid and denosumab in spinal metastases and cancer (3 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Primary: Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained in good health. Planned start Jul 2020; status: authorised.
02
Drugs
zoledronic aciddenosumab
03
Conditions
spinal metastasescancer
Beyond the preview
Go deeper on 2024-513248-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513248-27-00.